Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Invested Capital (2016 - 2025)

Catalyst Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $954.3 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 31.15% year-over-year to $954.3 million; the TTM value through Dec 2025 reached $954.3 million, up 31.15%, while the annual FY2025 figure was $954.3 million, 31.15% up from the prior year.
  • Invested Capital reached $954.3 million in Q4 2025 per CPRX's latest filing, up from $920.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $954.3 million in Q4 2025 to a low of $178.7 million in Q1 2021.
  • Average Invested Capital over 5 years is $466.7 million, with a median of $361.9 million recorded in 2023.
  • Peak YoY movement for Invested Capital: grew 21.95% in 2021, then soared 89.63% in 2024.
  • A 5-year view of Invested Capital shows it stood at $206.8 million in 2021, then surged by 45.25% to $300.4 million in 2022, then grew by 29.11% to $387.9 million in 2023, then soared by 87.59% to $727.6 million in 2024, then surged by 31.15% to $954.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Invested Capital are $954.3 million (Q4 2025), $920.2 million (Q3 2025), and $856.0 million (Q2 2025).